Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Core Viewpoint - Ensysce Biosciences, Inc. has initiated a pivotal Phase 3 clinical trial for its lead product candidate PF614, aimed at providing effective pain relief with built-in abuse protection [1] Group 1: Clinical Trial Details - The first patient has been enrolled in the Phase 3 clinical trial, named PF614-301 [1] - The study is a multicenter, randomized, double-blind, placebo- and active-controlled trial [1] - The trial aims to evaluate the efficacy and safety of PF614 for treating moderate to severe pain following abdominoplasty [1] Group 2: Product Features - PF614 is designed to deliver strong and consistent post-surgical pain relief [1] - The product incorporates an innovative chemical mechanism intended to reduce the risk of abuse and overdose [1]